Amgen to Present at Citi's 2026 Virtual Oncology Leadership Summit

Biotech giant to showcase oncology pipeline and innovations at industry conference

Published on Feb. 13, 2026

Got story updates? Submit your updates here. ›

Amgen, a leading biopharmaceutical company, announced that it will present at Citi's 2026 Virtual Oncology Leadership Summit on February 18, 2026. Jean-Charles Soria, senior vice president of oncology within global development at Amgen, will deliver the presentation, which will be webcast live and available for replay afterwards.

Why it matters

Amgen's participation in this high-profile oncology conference underscores its commitment to advancing innovative cancer treatments and its position as a major player in the biopharmaceutical industry. The presentation will provide investors and the public an opportunity to learn about Amgen's latest oncology pipeline and development efforts.

The details

The webcast presentation will take place at 12:15 p.m. PT on Wednesday, February 18, 2026. It can be accessed on Amgen's website under the Investors section. Amgen regularly presents at investor and medical conferences to share updates on its business and pipeline.

  • The presentation will take place on Wednesday, February 18, 2026 at 12:15 p.m. PT.

The players

Amgen

A leading biopharmaceutical company that discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases.

Jean-Charles Soria

Senior vice president of oncology within global development at Amgen, who will deliver the presentation at the Citi conference.

Got photos? Submit your photos here. ›

What’s next

The webcast presentation will be archived and available for replay for at least 90 days after the event, allowing investors and the public to access the information at their convenience.

The takeaway

Amgen's participation in the Citi Oncology Leadership Summit underscores its position as a leader in the biopharmaceutical industry and its commitment to advancing innovative cancer treatments through its robust oncology pipeline and development efforts.